Hu Yuqing, Liu Ping, Mu Zhanglei, Zhang Jianzhong . Effect of benvitimod on the proliferation of, inflammatory cytokine secretion by and skin barrier factor production by HaCaT cells[J]. Chinese Journal of Dermatology, 2020, 53(12): 984-991.doi:10.35541/cjd.20200048
Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients[J]. J Eur Acad Dermatol Venereol, 2016,30(5):729⁃747. doi: 10.1111/jdv.13599.
[2]
Napolitano M, Patruno C. Aryl hydrocarbon receptor (AhR) a possible target for the treatment of skin disease[J]. Med Hypotheses, 2018,116:96⁃100. doi: 10.1016/j.mehy.2018.05.001.
[3]
Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI⁃1001 in patients with mild to moderate psoriasis: results from a randomized double⁃blind placebo⁃controlled, phase II trial[J]. J Eur Acad Dermatol Venereol, 2012,26(12):1516⁃1521. doi: 10.1111/j.1468⁃ 3083.2011.04332.x.
[4]
Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural ahr agonist that resolves skin inflammation in mice and humans[J]. J Invest Dermatol, 2017,137(10):2110⁃2119. doi: 10.1016/j.jid.2017.05.004.
Zhao L, Chen X, Cai L, et al. Randomized, double⁃blind, placebo⁃controlled, multiple⁃dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis[J]. J Clin Pharm Ther, 2014,39(4):418⁃423. doi: 10.1111/jcpt.12158.
[7]
Silvestre Salvador JF, Romero⁃Pérez D, Encabo⁃Durán B. Atopic dermatitis in adults: a diagnostic challenge[J]. J Investig Allergol Clin Immunol, 2017,27(2):78⁃88. doi: 10.18176/jiaci. 0138.
[8]
Mu Z, Zhao Y, Liu X, et al. Molecular biology of atopic dermatitis[J]. Clin Rev Allergy Immunol, 2014,47(2):193⁃218. doi: 10. 1007/s12016⁃014⁃8415⁃1.
[9]
Sugiura A, Nomura T, Mizuno A, et al. Reevaluation of the non⁃lesional dry skin in atopic dermatitis by acute barrier disruption: an abnormal permeability barrier homeostasis with defective processing to generate ceramide[J]. Arch Dermatol Res, 2014,306(5):427⁃440. doi: 10.1007/s00403⁃013⁃1430⁃x.
[10]
Sandilands A, Sutherland C, Irvine AD, et al. Filaggrin in the frontline: role in skin barrier function and disease[J]. J Cell Sci, 2009,122(Pt 9):1285⁃1294. doi: 10.1242/ jcs.033969.
[11]
Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor[J]. J Dermatol Sci, 2015,80(2):83⁃88. doi: 10.1016/j.jdermsci.2015. 07.011.
[12]
Fardel O. Cytokines as molecular targets for aryl hydrocarbon receptor ligands: implications for toxicity and xenobiotic detoxification[J]. Expert Opin Drug Metab Toxicol, 2013,9(2):141⁃152. doi: 10.1517/17425255.2013. 738194.
[13]
Jeong SJ, Lim HS, Seo CS, et al. Anti⁃inflammatory actions of herbal formula Gyejibokryeong⁃hwan regulated by inhibiting chemokine production and STAT1 activation in HaCaT cells[J]. Biol Pharm Bull, 2015,38(3):425⁃434. doi: 10.1248/bpb.b14⁃00660.
[14]
Park JW, Lee HS, Lim Y, et al. Rhododendron album Blume extract inhibits TNF⁃α/IFN⁃γ⁃induced chemokine production via blockade of NF⁃κB and JAK/STAT activation in human epidermal keratinocytes[J]. Int J Mol Med, 2018,41(6):3642⁃3652. doi: 10.3892/ijmm.2018.3556.